明德生物收盘下跌3.15%，滚动市盈率54.67倍，总市值40.74亿元

Company Overview - Mingde Biological Technology Co., Ltd. focuses on the research, production, sales, and service of in vitro diagnostic reagents and instruments, covering three main areas: in vitro diagnostic reagents and instruments, critical care information solutions, and third-party medical testing services [1] - The company achieved a revenue of 350 million yuan in 2024, representing a year-on-year decrease of 53.30%, with a net profit of 74.52 million yuan, down 0.54% year-on-year, and a gross profit margin of 53.89% [1] Market Performance - As of April 28, Mingde Biological's stock closed at 17.52 yuan, down 3.15%, with a rolling price-to-earnings (PE) ratio of 54.67 times and a total market capitalization of 4.074 billion yuan [1] - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Mingde Biological at the 93rd position in the industry ranking [1][2] Capital Flow - On April 28, the net outflow of main funds for Mingde Biological was 688,300 yuan, although the overall trend over the past five days showed a net inflow of 14.56 million yuan [1]